# US 2010/0303827 A1 · Protein Formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303827 A1
- Document ID: US20100303827A1
- Status: Published application
- Kind: A1
- Application number: 12/744,745
- Filed: 2008-11-26
- Published: 2010-12-02
- Earliest claimed: 2007-11-28
- Assignees: One Medimmune Way
- Inventors: Monika S. Sharma, SR.; Ambarish Shah; Scott Hammond
- Web page: https://patentgrep.com/patent/US20100303827A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides stable lyophilized formulations of bispecific antibodies or fragments thereof.

## Claims

### Claim 1

A liquid pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The formulation of claim 1, wherein the first binding domain comprises the amino acid sequence of residues 283-525 of SEQ ID NO:5.

### Claim 4 (depends on 1)

The formulation of claim 1, wherein the second binding domain specifically binds an antigen chosen from CD19, CD20, CD22, EphA2, EphA4, INFR, ICOS, Ep-CAM, CEA, and IL-5 receptor.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The formulation of claim 4, wherein the second binding domain comprises the amino acid sequence of residues 28-277 of SEQ ID NO:5.

### Claim 7 (depends on 4)

The formulation of claim 4, wherein the bispecific antibody comprises the amino acid sequence of residues 28-525 of SEQ ID NO:5.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

The formulation of claim 1, wherein the formulation further comprises one or more of:
a) a buffering agent chosen from histidine, citrate, phosphate, glycine, and acetate;
b) a carbohydrate excipient chosen from sucrose, trehalose, lactose, mannitol, and raffinose; and
c) a surfactant chosen from Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 80.

### Claim at position 10

13-29. (canceled)

### Claim 30

A lyophilized pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.

### Claim 31 (depends on 30)

The formulation of claim 30, wherein the first binding domain comprises the amino acid sequence of residues 283-525 of SEQ ID NO:5.

### Claim 32 (depends on 30)

The formulation of claim 30, wherein the second binding domain specifically binds an antigen chosen from CD 19, CD20, CD22, EphA2, EphA4, INFR, ICOS, Ep-CAM, CEA, and IL-5 receptor.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The formulation of claim 32, wherein the second binding domain comprises the amino acid sequence of residues 28-277 of SEQ ID NO:5.

### Claim 35 (depends on 32)

The formulation of claim 32, wherein the bispecific antibody comprises the amino acid sequence of residues 28-525 of SEQ ID NO:5.

### Claim 36 (depends on 3035)

The formulation of claim 3035, wherein the formulation further comprises one or more of:
a) a buffering agent chosen from histidine, citrate, phosphate, glycine, and acetate;
b) a carbohydrate chosen from sucrose, trehalose, lactose, mannitol, and raffinose; and
c) a surfactant chosen from Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

### Claim at position 18

37-43. (canceled)

### Claim 44

A liquid reconstituted pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.

### Claim 45 (depends on 44)

The formulation of claim 44, wherein the first binding domain comprises the amino acid sequence of residues 283-525 of SEQ ID NO:5.

### Claim 46 (depends on 44)

The formulation of claim 44, wherein the second binding domain specifically binds an antigen chosen from CD 19, CD20, CD22, EphA2, EphA4, INFR, ICOS, Ep-CAM, CEA, and IL-5 receptor.

### Claim 47

(canceled)

### Claim 48 (depends on 46)

The formulation of claim 46, wherein the second binding domain comprises the amino acid sequence of residues 28-277 of SEQ ID NO:5.

### Claim 49 (depends on 46)

The formulation of claim 46, wherein the bispecific antibody comprises the amino acid sequence of residues 28-525 of SEQ ID NO:5.

### Claim at position 25

50-52. (canceled)

### Claim 53 (depends on 44)

The formulation of claim 44, wherein the formulation further comprises one or more of:
a) a buffering agent chosen from histidine, citrate, phosphate, glycine, and acetate;
b) a carbohydrate excipient chosen from sucrose, trehalose, lactose, mannitol, and raffinose; and
c) a surfactant chosen from Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.

### Claim at position 27

54-72. (canceled)

### Claim 73 (depends on 1)

A method of preventing, managing, treating or ameliorating B cell disorders or diseases such as, B cell malignancies, autoimmune diseases, graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in a human subject, said methods comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount of the formulation of claim 1.

### Claim at position 29

74-75. (canceled)

### Claim 76 (depends on 1)

A method of stabilizing a bispecific antibody, comprising: combining the antibody of claim 1 with lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.
